Bryn Pharma said that it has raised $11 million in an extension of the financing that raised over $17 million in October 2019 to fund activities related to its BRYN-NDS1C epinephrine nasal spray candidate, which is delivered via Aptar Pharma’s Bidose nasal device. According to Bryn, proceeds from this financing will be used for continued development of BRYN-NDS1C, as well as for regulatory and pre-commercialization activities.
Earlier this year, the company reported data from a Phase 1 PK/PD study of BRYN-NDS1C that compared the nasal spray to Mylan’s EpiPen. The company has said that it plans to submit a 505(b)(2) NDA for the nasal spray.
Bryn Pharma CEO David Dworaczyk commented, “This financing provides us further resources to continue building the value of Bryn Pharma and to bring our disruptive nasal epinephrine product to the large number of patients requiring protection from anaphylactic events. We are pleased with the enthusiastic response to this offering and to the continued support of investors as we forge ahead with this important initiative for anaphylactic patients.”
Read the Bryn Pharma press release.
